These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 20823828)
1. [Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia]. Uspenskaia OV; Iakhno NN; Belushkina NN Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):36-40. PubMed ID: 20823828 [TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Marksteiner J; Hinterhuber H; Humpel C Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711 [TBL] [Abstract][Full Text] [Related]
3. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. Le Bastard N; Van Buggenhout M; De Leenheir E; Martin JJ; De Deyn PP; Engelborghs S J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):923-4; author reply 924-5. PubMed ID: 17702886 [No Abstract] [Full Text] [Related]
4. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
5. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Nägga K; Gottfries J; Blennow K; Marcusson J Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Ivanoiu A; Sindic CJ Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663 [TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817 [TBL] [Abstract][Full Text] [Related]
10. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Engelborghs S; Le Bastard N J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896 [TBL] [Abstract][Full Text] [Related]
11. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
12. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Dean RA; Shaw LM Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774 [No Abstract] [Full Text] [Related]
13. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047 [TBL] [Abstract][Full Text] [Related]
14. [Neurochemical early and differential diagnostics for Alzheimer's disease]. Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429 [TBL] [Abstract][Full Text] [Related]
15. [The role of CSF markers in the early diagnosis of Alzheimer's disease]. Vos SJ; Visser PJ; Verhey FR Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322 [TBL] [Abstract][Full Text] [Related]
16. Biomarkers for the early diagnosis of Alzheimer's disease. de Leon MJ; Klunk W Lancet Neurol; 2006 Mar; 5(3):198-9. PubMed ID: 16488371 [No Abstract] [Full Text] [Related]
17. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away. Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612 [No Abstract] [Full Text] [Related]
19. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807 [TBL] [Abstract][Full Text] [Related]